Description: Eltrombopag (formerly AKR-501, YM477, AS 1670542 or E5501; trade name: Doptelet) is an orally-active small molecule thrombopoietin (TPO) receptor agonist that was used for the first time in 2008 to treat patients with chronic idiopathic thrombocytopenic purpura. Thrombopoietin (TPO) is the principal physiologic regulator of platelet production. As of May 2018, Eltrombopag was approved by US FDA to treat low blood platelet count (thrombocytopenia) in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure. AKR-501 specifically targeted the TPO receptor and stimulated megakaryocytopoiesis throughout the development and maturation of megakaryocytes just as rhTPO did. AKR-501, however, was shown to be effective only in humans and chimpanzees with high species specificity. References: Eur J Pharmacol. 2011 Jan 10;650(1):58-63; Eur J Haematol. 2009 Apr;82(4):247-54. Related CAS#:570406-98-3 (free base)

纯度：≥98%

CAS：570403-17-7